Cancer Chemotherapy and Pharmacology

, Volume 33, Issue 1, pp 43–47 | Cite as

Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines

  • Andreas Harstrick
  • Carsten Bokemeyer
  • Martin Scharnofkse
  • Gunnar Hapke
  • Dagmar Reile
  • Hans-Joachim Schmoll
Original Articles Cisplatin, Lobaplatin, Resistance, Testicular Carcinoma, Ovarian Carcinoma, Gastric Carcinoma

Abstract

Lobaplatin [1,2-diamminomethylcyclobutane-platinum(II) lactate] is a new platinum compound with interesting preclinical activity and apparently no nephro- or neurotoxicity that is currently undergoing clinical phase II studies. Little is known about the cross-resistance between cisplatin and lobaplatin. The activity of this new compound in comparison with cisplatin and carboplatin was evaluated in cisplatin-sensitive and cisplatin-resistant human testicular, gastric, and ovarian carcinoma cell lines using 96 h continuous drug exposure in a sulforhodamine-B assay. In three cisplatin-sensitive testicular carcinoma cell lines, lobaplatin and cisplatin showed comparable antitumor activity. The 50% growth-inhibitory concentrations (IC50 values) determined for cisplatin ranged from 0.1 to 0.4 μM, and those found for lobaplatin ranged from 0.25 to 0.5 μM. Carboplatin showed markedly lower cytotoxicity in all cell lines tested. Lobaplatin was not cross-resistant to cisplatin in a 10-fold cisplatin-resistant testicular carcinoma cell line and showed only weak cross-resistance in a 20-fold cisplatin-resistant ovarian carcinoma cell line. In contrast, complete cross-resistance between cisplatin and lobaplatin occurred in two cisplatin-resistant human gastric carcinoma cell lines, which were 3.3- and 9-fold resistant to cisplatin and 3.1- and 6.5-fold resistant to lobaplatin, respectively. Furthermore, lobaplatin showed significant activity against cisplatin-resistant human ovarian and testicular carcinoma xenografts in vivo. These data indicate a high level of activity for lobaplatin at clinically achievable concentrations in drug-sensitive testicular, ovarian, and gastric carcinoma cell lines and a lack of complete cross-resistance to cisplatin. Further clinical development of lobaplatin is clearly warranted.

Keywords

Carboplatin Carcinoma Cell Line Human Gastric Carcinoma Ovarian Carcinoma Cell Line Gastric Carcinoma Cell Line 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alberts DS, Mason L (1989) Carboplatin in the treatment of ovarian cancer. Semin Oncol 16 [Suppl 5]: 19–26Google Scholar
  2. 2.
    Asta Medica (1990) Clinical brochure for investigators: D-19 644. Asta Medica GmbH, FrankfurtGoogle Scholar
  3. 3.
    Bajorin DF, Sarosdy MF, Bosl GJ, Pfister DG, Mazumdar M, Motzer RJ, Scher HI, Geller NL, Fair WR, Herr H, Sogani P, Sheinfeld J, Russo P, Vlamis V, Carey R, Vogelzang NJ, Crawford ED, Bosl GJ (1993) A randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good risk germ cell tumors. J Clin Oncol 11: 598–606Google Scholar
  4. 4.
    Bunn PA (1989) Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol 16 [Suppl 5]: 27–33Google Scholar
  5. 5.
    Fiebig H, Berger DP, Mross K, Queisser W, Aulenbacher P, Hilgard P (1992) Lobaplatin (D-19 466): preclinical drug profile and results of the phase I study. Ann Oncol 3 [Suppl]: 143Google Scholar
  6. 6.
    Gietema JA, deVries EGE, Sleijfer DT, Willemse PHB, Guchelaar HJ, Uges DRA, Aulenbacher P, Voegeli R, Mulder NH (1991) A phase I study of 1,2-diammine-cyclobutane-platinum (II) lactate (D-19 466, lobaplatin) administered daily for five days. J Cancer Res Clin Oncol 1176 [Suppl 3]: S103Google Scholar
  7. 7.
    Hamilton TC, Winkler MA, Louie KC, et al (1985) Augmentation of Adriamycin, melphalan and cisplatin cytotoxicity in drug resistant and sensitive human ovarian carcinoma cell line by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 34: 2583–2586Google Scholar
  8. 8.
    Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ (1989) Comparison of the antitumor activity of cisplatin, carboplatin and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 63: 1079–1083Google Scholar
  9. 9.
    Loehrer PJ, Einhorn LH (1984) Cisplatin. Ann Intern Med 100: 704–713Google Scholar
  10. 10.
    Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M, Hamilton TC (1988) Increased DNA repair as a mechanism of acquired resistance tocis-diamminedichloroplatinum in human ovarian cancer cell lines. Cancer Res 48: 5713–5716Google Scholar
  11. 11.
    Medical Research Council Working Party (1987) A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 23: 375–377Google Scholar
  12. 12.
    Meijer C, Mulder NH, Timmer-Boscha H, Sluiter WJ, Meersma GJ, deVries EGE (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52: 6885–6889Google Scholar
  13. 13.
    Mross K, Meyberg F, Fiebig HH, Hamm K, Hieber U, Aulenbacher P, Hossfeld DK (1992) Pharmacokinetic and pharmacodynamic study with lobaplatin, a new platinum complex, after bolus administration. Onkologie 15: 139–146Google Scholar
  14. 14.
    Queisser W, Preusser P, Mross KB (1989) Phase II study with carboplatin in patients with advanced squamous cell carcinoma of the esophagus. Contrib Oncol 37: 184–190Google Scholar
  15. 15.
    Rogan AM, Hamilton TC, Young RC, Klecker RW, Ozols RF (1984) Reversal of Adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994–999Google Scholar
  16. 16.
    Skeehan P, Storeng R, Scudiero D, et al (1990) New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107–1112Google Scholar
  17. 17.
    Zwelling LA (1986) Cisplatin and new platinum analogs. In: Pinedo HM, Chabner BA (eds) Cancer chemotherapy, vol 8. Elsevier, Amsterdam New York, pp 97–116Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Andreas Harstrick
    • 1
  • Carsten Bokemeyer
    • 2
  • Martin Scharnofkse
    • 2
  • Gunnar Hapke
    • 2
  • Dagmar Reile
    • 2
  • Hans-Joachim Schmoll
    • 2
  1. 1.West German Cancer CenterEssen 1Germany
  2. 2.Department of Hematology and OncologyUniversity of Hannover Medical SchoolHannover 61Germany

Personalised recommendations